-- Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients -- -- Treatment with sotrovimab resulted in an 85% reduction
Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three
MONROVIA, Calif. & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc.
MONROVIA, Calif. --(BUSINESS WIRE)--May 25, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement
Xencor and Chugai Initiate Partnership for Optimized Antibodies Chugai licenses Xencor’s XmAb™ technology to enhance antibody efficacy Monrovia, CA – January 10, 2005 – Xencor today announced a license and collaboration agreement with Chugai Pharmaceutical Co., Ltd.
Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA February 23, 2009 Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.
MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology
MONROVIA, Calif. & HOUSTON --(BUSINESS WIRE)--Sep. 3, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced